Press release
Hematological Malignancies Disease Market 2022: Global Size,Supply-Demand,Product Type and End User Analysis To 2028- Affymetrix, SkylineDx, AgenaBio
With deep quantitative and qualitative analysis, the report provides encyclopedic and accurate research study on important aspects of the global Hematological Malignancies Disease market. It brings to light key factors affecting the growth of different segments and regions in the global Hematological Malignancies Disease market. It also offers SWOT, Porter's Five Forces, and PESTLE analysis to thoroughly examine the global Hematological Malignancies Disease market. It gives a detailed study on manufacturing cost, upstream and downstream buyers, distributors, marketing strategy, and marketing channel development trends of the global Hematological Malignancies Disease market. Furthermore, it provides strategic bits of advice and recommendations for players to ensure success in the global Hematological Malignancies Disease market.
Get PDF template of this report: https://www.qyresearch.com/sample-form/form/4392161/global-hematological-malignancies-disease-market
Competitive Landscape and Hematological Malignancies Disease Market Share Analysis
Hematological Malignancies Disease market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Hematological Malignancies Disease business, the date to enter into the Hematological Malignancies Disease market, Hematological Malignancies Disease product introduction, recent developments, etc.
Hematological Malignancies Disease Market Leading Players
Affymetrix, SkylineDx, AgenaBio, Signal Genetics, Pfizer, Roche, Sanofi-Aventis, Cancer Genetics Inc, Illumina, NeoGenomics, Exiqon, Regulus Therapeutics, Rosetta Genomics, Sequenta, Takeda Pharma, Celgene, Amgen, Ono Pharma, Abbott, BMS, Mundipharma, Novartis, MorphoSys
Product Type:
Chemotherapy, Immunotherapy, Targeted Therapy, Radiotherapy, Stem Cell Transplantation, Others Hematological Malignancies Disease
By Application:
Leukemia, Lymphoma, Myeloma, Others
Regions and Countries
• The Middle East and Africa (GCC Countries and Egypt)
• North America (the United States, Mexico, and Canada)
• South America (Brazil etc.)
• Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
• Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)
Key Questions Answered
• What is the size and CAGR of the global Hematological Malignancies Disease market?
• Which are the leading segments of the global Hematological Malignancies Disease market?
• What are the key driving factors of the most profitable regional market?
• What is the nature of competition in the global Hematological Malignancies Disease market?
• How will the global Hematological Malignancies Disease market advance in the coming years?
• What are the main strategies adopted in the global Hematological Malignancies Disease market?
Enquire for customization in Report @https://www.qyresearch.com/customize-request/form/4392161/global-hematological-malignancies-disease-market
Table of Contents
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hematological Malignancies Disease Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Chemotherapy
1.2.3 Immunotherapy
1.2.4 Targeted Therapy
1.2.5 Radiotherapy
1.2.6 Stem Cell Transplantation
1.2.7 Others
1.3 Market by Application
1.3.1 Global Hematological Malignancies Disease Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Leukemia
1.3.3 Lymphoma
1.3.4 Myeloma
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered 2 Global Growth Trends
2.1 Global Hematological Malignancies Disease Market Perspective (2017-2028)
2.2 Hematological Malignancies Disease Growth Trends by Region
2.2.1 Hematological Malignancies Disease Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Hematological Malignancies Disease Historic Market Size by Region (2017-2022)
2.2.3 Hematological Malignancies Disease Forecasted Market Size by Region (2023-2028)
2.3 Hematological Malignancies Disease Market Dynamics
2.3.1 Hematological Malignancies Disease Industry Trends
2.3.2 Hematological Malignancies Disease Market Drivers
2.3.3 Hematological Malignancies Disease Market Challenges
2.3.4 Hematological Malignancies Disease Market Restraints 3 Competition Landscape by Key Players
3.1 Global Top Hematological Malignancies Disease Players by Revenue
3.1.1 Global Top Hematological Malignancies Disease Players by Revenue (2017-2022)
3.1.2 Global Hematological Malignancies Disease Revenue Market Share by Players (2017-2022)
3.2 Global Hematological Malignancies Disease Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hematological Malignancies Disease Revenue
3.4 Global Hematological Malignancies Disease Market Concentration Ratio
3.4.1 Global Hematological Malignancies Disease Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematological Malignancies Disease Revenue in 2021
3.5 Hematological Malignancies Disease Key Players Head office and Area Served
3.6 Key Players Hematological Malignancies Disease Product Solution and Service
3.7 Date of Enter into Hematological Malignancies Disease Market
3.8 Mergers & Acquisitions, Expansion Plans 4 Hematological Malignancies Disease Breakdown Data by Type
4.1 Global Hematological Malignancies Disease Historic Market Size by Type (2017-2022)
4.2 Global Hematological Malignancies Disease Forecasted Market Size by Type (2023-2028) 5 Hematological Malignancies Disease Breakdown Data by Application
5.1 Global Hematological Malignancies Disease Historic Market Size by Application (2017-2022)
5.2 Global Hematological Malignancies Disease Forecasted Market Size by Application (2023-2028) 6 North America
6.1 North America Hematological Malignancies Disease Market Size (2017-2028)
6.2 North America Hematological Malignancies Disease Market Size by Type
6.2.1 North America Hematological Malignancies Disease Market Size by Type (2017-2022)
6.2.2 North America Hematological Malignancies Disease Market Size by Type (2023-2028)
6.2.3 North America Hematological Malignancies Disease Market Share by Type (2017-2028)
6.3 North America Hematological Malignancies Disease Market Size by Application
6.3.1 North America Hematological Malignancies Disease Market Size by Application (2017-2022)
6.3.2 North America Hematological Malignancies Disease Market Size by Application (2023-2028)
6.3.3 North America Hematological Malignancies Disease Market Share by Application (2017-2028)
6.4 North America Hematological Malignancies Disease Market Size by Country
6.4.1 North America Hematological Malignancies Disease Market Size by Country (2017-2022)
6.4.2 North America Hematological Malignancies Disease Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada 7 Europe
7.1 Europe Hematological Malignancies Disease Market Size (2017-2028)
7.2 Europe Hematological Malignancies Disease Market Size by Type
7.2.1 Europe Hematological Malignancies Disease Market Size by Type (2017-2022)
7.2.2 Europe Hematological Malignancies Disease Market Size by Type (2023-2028)
7.2.3 Europe Hematological Malignancies Disease Market Share by Type (2017-2028)
7.3 Europe Hematological Malignancies Disease Market Size by Application
7.3.1 Europe Hematological Malignancies Disease Market Size by Application (2017-2022)
7.3.2 Europe Hematological Malignancies Disease Market Size by Application (2023-2028)
7.3.3 Europe Hematological Malignancies Disease Market Share by Application (2017-2028)
7.4 Europe Hematological Malignancies Disease Market Size by Country
7.4.1 Europe Hematological Malignancies Disease Market Size by Country (2017-2022)
7.4.2 Europe Hematological Malignancies Disease Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries 8 Asia-Pacific
8.1 Asia-Pacific Hematological Malignancies Disease Market Size (2017-2028)
8.2 Asia-Pacific Hematological Malignancies Disease Market Size by Type
8.2.1 Asia-Pacific Hematological Malignancies Disease Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Hematological Malignancies Disease Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Hematological Malignancies Disease Market Share by Type (2017-2028)
8.3 Asia-Pacific Hematological Malignancies Disease Market Size by Application
8.3.1 Asia-Pacific Hematological Malignancies Disease Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Hematological Malignancies Disease Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Hematological Malignancies Disease Market Share by Application (2017-2028)
8.4 Asia-Pacific Hematological Malignancies Disease Market Size by Region
8.4.1 Asia-Pacific Hematological Malignancies Disease Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Hematological Malignancies Disease Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia 9 Latin America
9.1 Latin America Hematological Malignancies Disease Market Size (2017-2028)
9.2 Latin America Hematological Malignancies Disease Market Size by Type
9.2.1 Latin America Hematological Malignancies Disease Market Size by Type (2017-2022)
9.2.2 Latin America Hematological Malignancies Disease Market Size by Type (2023-2028)
9.2.3 Latin America Hematological Malignancies Disease Market Share by Type (2017-2028)
9.3 Latin America Hematological Malignancies Disease Market Size by Application
9.3.1 Latin America Hematological Malignancies Disease Market Size by Application (2017-2022)
9.3.2 Latin America Hematological Malignancies Disease Market Size by Application (2023-2028)
9.3.3 Latin America Hematological Malignancies Disease Market Share by Application (2017-2028)
9.4 Latin America Hematological Malignancies Disease Market Size by Country
9.4.1 Latin America Hematological Malignancies Disease Market Size by Country (2017-2022)
9.4.2 Latin America Hematological Malignancies Disease Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil 10 Middle East & Africa
10.1 Middle East & Africa Hematological Malignancies Disease Market Size (2017-2028)
10.2 Middle East & Africa Hematological Malignancies Disease Market Size by Type
10.2.1 Middle East & Africa Hematological Malignancies Disease Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Hematological Malignancies Disease Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Hematological Malignancies Disease Market Share by Type (2017-2028)
10.3 Middle East & Africa Hematological Malignancies Disease Market Size by Application
10.3.1 Middle East & Africa Hematological Malignancies Disease Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Hematological Malignancies Disease Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Hematological Malignancies Disease Market Share by Application (2017-2028)
10.4 Middle East & Africa Hematological Malignancies Disease Market Size by Country
10.4.1 Middle East & Africa Hematological Malignancies Disease Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Hematological Malignancies Disease Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE 11 Key Players Profiles
11.1 Affymetrix
11.1.1 Affymetrix Company Details
11.1.2 Affymetrix Business Overview
11.1.3 Affymetrix Hematological Malignancies Disease Introduction
11.1.4 Affymetrix Revenue in Hematological Malignancies Disease Business (2017-2022)
11.1.5 Affymetrix Recent Developments
11.2 SkylineDx
11.2.1 SkylineDx Company Details
11.2.2 SkylineDx Business Overview
11.2.3 SkylineDx Hematological Malignancies Disease Introduction
11.2.4 SkylineDx Revenue in Hematological Malignancies Disease Business (2017-2022)
11.2.5 SkylineDx Recent Developments
11.3 AgenaBio
11.3.1 AgenaBio Company Details
11.3.2 AgenaBio Business Overview
11.3.3 AgenaBio Hematological Malignancies Disease Introduction
11.3.4 AgenaBio Revenue in Hematological Malignancies Disease Business (2017-2022)
11.3.5 AgenaBio Recent Developments
11.4 Signal Genetics
11.4.1 Signal Genetics Company Details
11.4.2 Signal Genetics Business Overview
11.4.3 Signal Genetics Hematological Malignancies Disease Introduction
11.4.4 Signal Genetics Revenue in Hematological Malignancies Disease Business (2017-2022)
11.4.5 Signal Genetics Recent Developments
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Hematological Malignancies Disease Introduction
11.5.4 Pfizer Revenue in Hematological Malignancies Disease Business (2017-2022)
11.5.5 Pfizer Recent Developments
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Hematological Malignancies Disease Introduction
11.6.4 Roche Revenue in Hematological Malignancies Disease Business (2017-2022)
11.6.5 Roche Recent Developments
11.7 Sanofi-Aventis
11.7.1 Sanofi-Aventis Company Details
11.7.2 Sanofi-Aventis Business Overview
11.7.3 Sanofi-Aventis Hematological Malignancies Disease Introduction
11.7.4 Sanofi-Aventis Revenue in Hematological Malignancies Disease Business (2017-2022)
11.7.5 Sanofi-Aventis Recent Developments
11.8 Cancer Genetics Inc
11.8.1 Cancer Genetics Inc Company Details
11.8.2 Cancer Genetics Inc Business Overview
11.8.3 Cancer Genetics Inc Hematological Malignancies Disease Introduction
11.8.4 Cancer Genetics Inc Revenue in Hematological Malignancies Disease Business (2017-2022)
11.8.5 Cancer Genetics Inc Recent Developments
11.9 Illumina
11.9.1 Illumina Company Details
11.9.2 Illumina Business Overview
11.9.3 Illumina Hematological Malignancies Disease Introduction
11.9.4 Illumina Revenue in Hematological Malignancies Disease Business (2017-2022)
11.9.5 Illumina Recent Developments
11.10 NeoGenomics
11.10.1 NeoGenomics Company Details
11.10.2 NeoGenomics Business Overview
11.10.3 NeoGenomics Hematological Malignancies Disease Introduction
11.10.4 NeoGenomics Revenue in Hematological Malignancies Disease Business (2017-2022)
11.10.5 NeoGenomics Recent Developments
11.11 Exiqon
11.11.1 Exiqon Company Details
11.11.2 Exiqon Business Overview
11.11.3 Exiqon Hematological Malignancies Disease Introduction
11.11.4 Exiqon Revenue in Hematological Malignancies Disease Business (2017-2022)
11.11.5 Exiqon Recent Developments
11.12 Regulus Therapeutics
11.12.1 Regulus Therapeutics Company Details
11.12.2 Regulus Therapeutics Business Overview
11.12.3 Regulus Therapeutics Hematological Malignancies Disease Introduction
11.12.4 Regulus Therapeutics Revenue in Hematological Malignancies Disease Business (2017-2022)
11.12.5 Regulus Therapeutics Recent Developments
11.13 Rosetta Genomics
11.13.1 Rosetta Genomics Company Details
11.13.2 Rosetta Genomics Business Overview
11.13.3 Rosetta Genomics Hematological Malignancies Disease Introduction
11.13.4 Rosetta Genomics Revenue in Hematological Malignancies Disease Business (2017-2022)
11.13.5 Rosetta Genomics Recent Developments
11.14 Sequenta
11.14.1 Sequenta Company Details
11.14.2 Sequenta Business Overview
11.14.3 Sequenta Hematological Malignancies Disease Introduction
11.14.4 Sequenta Revenue in Hematological Malignancies Disease Business (2017-2022)
11.14.5 Sequenta Recent Developments
11.15 Takeda Pharma
11.15.1 Takeda Pharma Company Details
11.15.2 Takeda Pharma Business Overview
11.15.3 Takeda Pharma Hematological Malignancies Disease Introduction
11.15.4 Takeda Pharma Revenue in Hematological Malignancies Disease Business (2017-2022)
11.15.5 Takeda Pharma Recent Developments
11.16 Celgene
11.16.1 Celgene Company Details
11.16.2 Celgene Business Overview
11.16.3 Celgene Hematological Malignancies Disease Introduction
11.16.4 Celgene Revenue in Hematological Malignancies Disease Business (2017-2022)
11.16.5 Celgene Recent Developments
11.17 Amgen
11.17.1 Amgen Company Details
11.17.2 Amgen Business Overview
11.17.3 Amgen Hematological Malignancies Disease Introduction
11.17.4 Amgen Revenue in Hematological Malignancies Disease Business (2017-2022)
11.17.5 Amgen Recent Developments
11.18 Ono Pharma
11.18.1 Ono Pharma Company Details
11.18.2 Ono Pharma Business Overview
11.18.3 Ono Pharma Hematological Malignancies Disease Introduction
11.18.4 Ono Pharma Revenue in Hematological Malignancies Disease Business (2017-2022)
11.18.5 Ono Pharma Recent Developments
11.19 Abbott
11.19.1 Abbott Company Details
11.19.2 Abbott Business Overview
11.19.3 Abbott Hematological Malignancies Disease Introduction
11.19.4 Abbott Revenue in Hematological Malignancies Disease Business (2017-2022)
11.19.5 Abbott Recent Developments
11.20 BMS
11.20.1 BMS Company Details
11.20.2 BMS Business Overview
11.20.3 BMS Hematological Malignancies Disease Introduction
11.20.4 BMS Revenue in Hematological Malignancies Disease Business (2017-2022)
11.20.5 BMS Recent Developments
11.21 Mundipharma
11.21.1 Mundipharma Company Details
11.21.2 Mundipharma Business Overview
11.21.3 Mundipharma Hematological Malignancies Disease Introduction
11.21.4 Mundipharma Revenue in Hematological Malignancies Disease Business (2017-2022)
11.21.5 Mundipharma Recent Developments
11.22 Novartis
11.22.1 Novartis Company Details
11.22.2 Novartis Business Overview
11.22.3 Novartis Hematological Malignancies Disease Introduction
11.22.4 Novartis Revenue in Hematological Malignancies Disease Business (2017-2022)
11.22.5 Novartis Recent Developments
11.23 MorphoSys
11.23.1 MorphoSys Company Details
11.23.2 MorphoSys Business Overview
11.23.3 MorphoSys Hematological Malignancies Disease Introduction
11.23.4 MorphoSys Revenue in Hematological Malignancies Disease Business (2017-2022)
11.23.5 MorphoSys Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
Place Your Order Here at USD(4900):
https://www.qyresearch.com/settlement/pre/1c0743df851f87c347e9b4c238864691,0,1,global-hematological-malignancies-disease-market
Contact US:
QY Research, INC.
17890 Castleton,
Suite 218,
City of industry, CA - 91748
USA: +1 626 295 2442
Email: enquiry@qyresearch.com
Web: http://www.qyresearch.com
: About Us:
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hematological Malignancies Disease Market 2022: Global Size,Supply-Demand,Product Type and End User Analysis To 2028- Affymetrix, SkylineDx, AgenaBio here
News-ID: 2561511 • Views: …
More Releases from QY Research, Inc
Global High Pressure Commercial Toilet Market Insights - Industry Share, Sales P …
High Pressure Commercial Toilet also means pressure-flushing toilets. Pressure-flushing toilets are especially common in cities in the U.S. The ceramic tank is not used as a water tank. It holds a plastic pressure vessel of maybe one-third to one-half the ceramic tank"s volume. That pressure tank contains a sealed air bladder. When the tank is filled from the water supply line, the tank fills with water until the air bladder…
Global Twin-Screw Pumps Market Insights - Industry Share, Sales Projections, and …
Twin-Screw Pumps is a displacement pump consisting of a casing containing two parallel screws with intermeshing threads fitted to prevent backward movement of fluid
The global Twin-Screw Pumps market was valued at US$ 503 million in 2023 and is anticipated to reach US$ 629 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
The top five global producers of twin-screw pumps are Colfax, ITT Bornemann, Flowserve, SPX Flow…
Global Strain Gauge Sensors Market Insights - Industry Share, Sales Projections, …
A strain gauge (or strain gage) is a sensor whose resistance varies with applied force; it converts force, pressure, tension, weight, etc., into a change in electrical resistance which can then be measured. When external forces are applied to a stationary object, stress and strain are the result. Stress is defined as the object"s internal Strain Gauge forces, and strain is defined as the displacement and deformation that occur.
The global…
Global Automatic Soap Dispensers Market Insights - Industry Share, Sales Project …
Automatic soap dispensers (also known as touchless or no-touch soap dispensers) dispense a controlled amount of soap solution (or a similar liquid such as a hand sanitizer). They are often used in conjunction with automatic faucets in public restrooms. They function to conserve the amount of soap used and stem infectious disease transmission.
The global Automatic Soap Dispensers market was valued at US$ million in 2023 and is anticipated to reach…
More Releases for Hematological
Global Hematological Malignancies Biotherapeutics Market
According to a new market research report published by Global Market Estimates, the Global Hematological Malignancies Biotherapeutics Market is projected to grow at a CAGR value of 10.8% from 2022 and 2027. The hematological malignancies biotherapeutics market is driven mainly by the growing incidence of blood cancer, increasing investment in cancer research, growing cancer awareness initiatives, and the growing number of specialized cancer treatment facilities.
Browse 151 Market Data Tables and…
Hematological Malignancies Market grows with growing prevalence of hematological …
The global hematological malignancies market is highly competitive in nature and is characterized by a consolidated nature, owing to the presence of a few players holding a large share of the overall market, states a research study by Transparency Market Research. The leading players operating in the global market, including Roche, Celgene, Novartis, and AbbVie are anticipated to remain dominant throughout the forecast period. In order to maintain their position…
Hematological Cancers Market Review with Comparative Analysis
Hematological cancer, commonly known as hematological malignancy, is a class of cancer that affects the lymph nodes, blood, and bone marrow. It includes numerous forms such as lymphoma, leukemia, and myeloma. Leukemia is a malignancy in which abnormal white blood cells are formed in the bone marrow. Lymphoma is a blood cancer that develops in the lymphatic system. Myeloma is a cancer associated with the plasma of the white blood…
Increasing Incidence of Hematological Cancers is Expected to Boost the Global He …
Hematological cancer, commonly known as hematological malignancy, is a class of cancer that affects the lymph nodes, blood, and bone marrow. It includes numerous forms such as lymphoma, leukemia, and myeloma. Leukemia is a malignancy in which abnormal white blood cells are formed in the bone marrow. Lymphoma is a blood cancer that develops in the lymphatic system.
Myeloma is a cancer associated with the plasma of the white blood…
Hematological Cancers Market: Increasing Incidence of Hematological Cancers is E …
Hematological cancer, commonly known as hematological malignancy, is a class of cancer that affects the lymph nodes, blood, and bone marrow. It includes numerous forms such as lymphoma, leukemia, and myeloma. Leukemia is a malignancy in which abnormal white blood cells are formed in the bone marrow. Lymphoma is a blood cancer that develops in the lymphatic system.
Myeloma is a cancer associated with the plasma of the white blood…
Rapidly Increasing Hematological Cancer Prevalence among the Population Drives t …
Hematological cancer, commonly known as hematological malignancy, is a class of cancer that affects the lymph nodes, blood, and bone marrow. It includes numerous forms such as lymphoma, leukemia, and myeloma. Leukemia is a malignancy in which abnormal white blood cells are formed in the bone marrow. Lymphoma is a blood cancer that develops in the lymphatic system. Myeloma is a cancer associated with the plasma of the white blood…
